Skip to main content

Table 1 HPV type-specific distribution by cervical cytology

From: Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study

HPV type Cervical cytology
Overalla Normal ASCUS+b LSIL HSIL HSIL+c
Study Sample size Positive Prevalence (95% CI) Study Sample size Positive Prevalence (95% CI) Study Sample size Positive Prevalence (95% CI) Study Sample size Positive Prevalence (95% CI) Study Sample size Positive Prevalence (95% CI) Study Sample size Positive Prevalence (95% CI)
High-risk HPV-16 23 16,700 3,247 19.4 (18.8–20.0) 17 8,627 1,188 13.8 (13.0–14.5) 18 4,185 635 15.2 (14.1–16.3) 17 1,293 218 16.9 (14.8–18.9) 14 1,061 375 35.3 (32.5–38.2) 13 1,534 831 54.2 (51.7–56.7)
HPV-18 22 16,188 1,126 7.0 (6.6–7.3) 16 8,364 571 6.8 (6.3–7.4) 17 4,026 238 5.9 (5.2–6.6) 16 1,238 83 6.7 (5.3–8.1) 13 1,022 73 7.1 (5.6–8.7) 13 1,534 161 10.5 (9.0–12.0)
HPV-26 5 9808 26 0.3 (0.2–0.4) 4 6,193 16 0.3 (0.1–0.4) 4 2,753 7 0.3 (0.1–0.4) 5 587 3 0.5 (0.0–1.1) 3 181 0 0.0 (0.0–0.0) 0 0 0 NA
HPV-31 18 15,033 483 3.2 (2.9–3.5) 12 7,912 227 2.9 (2.5–3.2) 13 3,772 142 3.8 (3.2–4.4) 12 1,003 21 2.1 (1.2–3.0) 9 868 32 3.7 (2.4–4.9) 11 1,478 61 4.1 (3.1–5.1)
HPV-33 19 15,138 555 3.7 (3.4–4.0) 13 7,936 222 2.8 (2.4–3.2) 14 3,795 142 3.7 (3.1–4.3) 13 1,040 38 3.7 (2.5–4.8) 10 889 67 7.5 (5.8–9.3) 11 1,478 86 5.8 (4.6–7.0)
HPV-35 20 15,687 585 3.7 (3.4–4.0) 14 8,204 308 3.8 (3.3–4.2) 15 3,886 152 3.9 (3.3–4.5) 14 1,106 35 3.2 (2.1–4.2) 11 968 52 5.4 (4.0–6.8) 12 1,523 38 2.5 (1.7–3.3)
HPV-39 19 14,455 647 4.5 (4.1–4.8) 13 7,523 442 5.9 (5.3–6.4) 14 3,661 134 3.7 (3.1–4.3) 13 997 46 4.6 (3.3–5.9) 10 837 11 1.3 (0.5–2.1) 11 1,437 14 1.0 (0.5–1.5)
HPV-45 15 13,906 263 1.9 (1.7–2.1) 11 7,579 152 2.0 (1.7–2.3) 11 3,248 52 1.6 (1.2–2.0) 11 854 14 1.6 (0.8–2.5) 8 835 11 1.3 (0.5–2.1) 10 1,390 34 2.4 (1.6–3.3)
HPV-51 18 15,062 788 5.2 (4.9–5.6) 13 7,792 441 5.7 (5.1–6.2) 14 3,856 204 5.3 (4.6–6.0) 14 1,140 104 9.1 (7.5–10.8) 11 901 34 3.8 (2.5–5.0) 10 1,349 5 0.4 (0.0–0.7)
HPV-52 23 16,700 1,593 9.5 (9.1–10.0) 17 8,627 842 9.8 (9.1–10.4) 18 4,185 493 11.8 (10.8–12.8) 17 1,293 113 8.7 (7.2–10.3) 14 1,061 95 9.0 (7.2–10.7) 13 1,534 50 3.3 (2.4–4.1)
HPV-53 14 13,781 1,474 10.7 (10.2–11.2) 10 7,312 956 13.1 (12.3–13.8) 12 3,633 362 10.0 (9.0–10.9) 11 964 115 11.9 (9.9–14.0) 8 699 26 3.7 (2.3–5.1) 8 1,173 15 1.3 (0.6–1.9)
HPV-56 21 15,323 845 5.5 (5.2–5.9) 15 7,870 465 5.9 (5.4–6.4) 16 3,870 215 5.6 (4.8–6.3) 15 1,154 119 10.3 (8.6–12.1) 12 947 23 2.4 (1.4–3.4) 12 1,482 23 1.6 (0.9–2.2)
HPV-58 23 16,700 1,790 10.7 (10.2–11.2) 17 8,627 875 10.1 (9.5–10.8) 18 4,185 477 11.4 (10.4–12.4) 17 1,293 142 11.0 (9.3–12.7) 14 1,061 180 17.0 (14.7–19.2) 13 1,534 116 7.6 (6.2–8.9)
HPV-59 16 13,602 266 2.0 (1.7–2.2) 11 6,873 159 2.3 (2.0–2.7) 13 3,635 75 2.1 (1.6–2.5) 12 956 13 1.4 (0.6–2.1) 9 814 5 0.6 (0.1–1.2) 8 1,324 14 1.1 (0.5–1.6)
HPV-66 16 13,394 575 4.3 (3.9–4.6) 10 6,795 330 4.9 (4.3–5.4) 13 3,635 152 4.2 (3.5–4.8) 11 881 62 7.0 (5.3–8.7) 8 750 14 1.9 (0.9–2.8) 8 1,333 17 1.3 (0.7–1.9)
HPV-68 16 13,615 900 6.6 (6.2–7.0) 11 6,873 623 9.1 (8.4–9.7) 11 3,537 209 5.9 (5.1–6.7) 12 956 46 4.8 (3.5–6.2) 9 814 11 1.4 (0.6–2.1) 9 1,412 11 0.8 (0.3–1.2)
HPV-73 3 9,340 55 0.6 (0.4–0.7) 2 5,836 37 0.6 (0.4–0.8) 2 2,281 15 0.7 (0.3–1.0) 2 390 3 0.8 (0.0–1.6) 1 127 0 0.0 (0.0–0.0) 1 706 0 0.0 (0.0–0.0)
HPV-82 4 9,887 159 1.6 (1.4–1.9) 4 6,178 104 1.7 (1.4–2.0) 4 2,860 44 1.5 (1.1–2.0) 4 601 7 1.2 (0.3–2.0) 3 233 4 1.7 (0.0–3.4) 1 15 0 0.0 (0.0–0.0)
Low-risk HPV-6 8 3,319 65 2.0 (1.5–2.4) 6 926 34 3.7 (2.5–4.9) 7 948 15 1.6 (0.8–2.4) 7 392 7 1.8 (0.5–3.1) 5 529 3 0.6 (0.0–1.2) 5 524 6 1.1 (0.2–2.1)
HPV-11 9 4,260 44 1.0 (0.7–1.3) 6 896 11 1.2 (0.5–1.9) 6 964 9 0.9 (0.3–1.5) 7 490 9 1.8 (0.6–3.0) 6 608 10 1.6 (0.6–2.7) 6 1,302 5 0.4 (0.0–0.7)
HPV-40 9 3,543 34 1.0 (0.6–1.3) 7 840 14 1.7 (0.8–2.5) 6 1,010 6 0.6 (0.1–1.1) 7 317 0 0.0 (0.0–0.0) 6 620 8 1.3 (0.4–2.2) 6 603 6 1.0 (0.2–1.8)
HPV-42 6 2,796 19 0.7 (0.4–1.0) 6 886 6 0.7 (0.1–1.2) 6 757 6 0.8 (0.2–1.4) 6 402 5 1.2 (0.2–2.3) 4 295 2 0.7 (0.0–1.6) 5 456 0 0.0 (0.0–0.0)
HPV-43 8 3,153 27 0.9 (0.5–1.2) 8 1,013 11 1.1 (0.4–1.7) 7 760 12 1.6 (0.7–2.5) 8 480 2 0.4 (0.2–1.0) 6 365 2 0.5 (0.0–1.3) 6 535 0 0.0 (0.0–0.0)
HPV-44 8 3,152 14 0.4 (0.2–0.7) 6 631 3 0.5 (0.1–1.0) 6 626 3 0.5 (0.0–1.0) 6 328 1 0.3 (0.0–0.9) 4 326 3 0.9 (0.0–2.0) 7 1,241 4 0.3 (0.0–0.6)
HPV-54 7 2,928 75 2.6 (2.0–3.1) 4 704 33 4.7 (3.1–6.2) 6 1,079 31 2.9 (1.9–3.9) 5 349 1 0.3 (0.0–0.8) 3 407 2 0.5 (0.0–1.2) 4 389 8 2.1 (0.6–3.5)
HPV-61 2 1,069 29 2.7 (1.7–3.7) 2 357 13 3.6 (1.7–5.6) 2 472 12 2.5 (1.1–4.0) 2 186 4 2.2 (0.1–4.2) 2 54 0 0.0 (0.0–0.0) 0 0 0 NA
HPV-70 10 9,827 768 7.8 (7.3–8.3) 7 4,200 447 10.6 (9.7–11.6) 8 3,221 258 8.0 (7.1–8.9) 8 672 43 6.4 (4.5–8.2) 6 601 15 2.5 (1.2–3.7) 6 1,110 5 0.5 (0.1–0.8)
HPV-72 3 755 8 1.1 (0.3–1.8) 3 206 5 2.4 (0.3–4.5) 3 217 2 0.9 (0.0–2.2) 3 162 1 0.6 (0.0–1.8) 3 140 0 0.0 (0.0–0.0) 1 15 0 0.0 (0.0–0.0)
HPV-81 4 1,719 24 1.4 (0.8–2.0) 4 598 11 1.8 (0.8–2.9) 4 647 9 1.4 (0.5–2.3) 4 285 4 1.4 (0.0–2.8) 3 152 0 0.0 (0.0–0.0) 3 37 0 0.0 (0.0–0.0)
Other 14 12,864 216 1.7 (1.5–1.9) 10 6,790 81 1.2 (0.9–1.5) 10 3,239 74 2.3 (1.8–2.8) 11 907 34 3.7 (2.5–5.0) 8 513 3 0.6 (0.0–1.2) 8 1,329 24 1.8 (1.1–2.5)
  1. ASCUS: Atypical squamous cells of uncertain significance; AGUS: Atypical glandular cells of undetermined significance; ASC-H: Atypical squamous cells without excluding HSIL; LSIL: Low-grade squamous intraepithelial lesion; HSIL: High-grade squamous intraepithelial lesion; CIS: Carcinoma in situ; ICC: Invasive cervical cancer; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; AIS: Adenocarcinoma in situ; 95% CI: 95% Confidence interval
  2. aOverall prevalence by cytology was calculated using the sum of all types obtained from the Pap results
  3. bASCUS including AGUS and ASC-H
  4. cHSIL including CIS, ICC, SCC, AC, AIS, and cervical cancer